INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

A prostate cancer screening program involving participants in the top decile of risk according to a polygenic risk score ...

INmune Bio (INMB) has partnered with the Cell and Gene Therapy Catapult to establish large-scale, commercial-ready manufacturing for its cell ...

Forecasts show cancer's global footprint expanding sharply, with annual case counts expected to rise 20% by 2030 and swell by ...

Researchers have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of tumor-infiltrating ...

A new multicenter study by researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with the Clinical ...

Theratechnologies Inc.’s THTX share price has surged by 47.37%, which has investors questioning if this is right time to sell.